Magnetar Financial LLC Has $6.78 Million Holdings in Boston Scientific Corporation $BSX

Magnetar Financial LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1,101.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 69,473 shares of the medical equipment provider’s stock after buying an additional 63,691 shares during the quarter. Magnetar Financial LLC’s holdings in Boston Scientific were worth $6,783,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gerber Kawasaki Wealth & Investment Management raised its holdings in shares of Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after acquiring an additional 99 shares during the period. Crown Wealth Group LLC lifted its position in shares of Boston Scientific by 4.7% in the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after acquiring an additional 100 shares in the last quarter. Claret Asset Management Corp boosted its stake in Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 102 shares during the period. Sound View Wealth Advisors Group LLC grew its position in Boston Scientific by 3.9% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 103 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC grew its position in Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 103 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research analyst reports. The Goldman Sachs Group set a $99.00 target price on Boston Scientific in a report on Thursday, February 5th. Oppenheimer lowered their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Royal Bank Of Canada reduced their price objective on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, Citigroup lowered their target price on Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $108.36.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Investor alert from TMCNet flags a securities‑fraud lawsuit and solicits investors to consider leading the class action. BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit
• Negative Sentiment: Bragar Eagel & Squire announces an investigation on behalf of long‑term BSX shareholders and invites contact regarding losses. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire
• Negative Sentiment: Rosen Law Firm public notice: a class action was filed covering the same class period and warns investors to secure counsel before the May 4 deadline. ROSEN Encourages Boston Scientific Investors to Secure Counsel
• Negative Sentiment: Robbins Geller Rudman & Dowd notifies investors of opportunity to seek lead‑plaintiff status in the filed class action (same class period). INVESTOR ALERT: RGRD Law
• Negative Sentiment: Faruqi & Faruqi issues a reminder about the May 4, 2026 deadline for investors to seek lead‑plaintiff appointment in the securities class action. Faruqi & Faruqi Reminder
• Negative Sentiment: Law Offices of Frank R. Cruz encourages BSX shareholders to inquire about a securities fraud class action — another solicitor notice piling on legal attention. Frank R. Cruz Notice
• Negative Sentiment: The Gross Law Firm posts a shareholder notice about a class action and the May 4 deadline to join as a plaintiff. Gross Law Firm Notice
• Negative Sentiment: Portnoy Law Firm announces a class action for investors who bought BSX during the stated class period and highlights the lead‑plaintiff deadline. Portnoy Law Firm Announcement
• Negative Sentiment: Bernstein Liebhard issues a shareholder alert confirming a securities‑fraud class action has been filed against Boston Scientific. Bernstein Liebhard Alert
• Negative Sentiment: Levi & Korsinsky notifies shareholders about the class action and encourages contact before the May 4 deadline. Levi & Korsinsky Notice
• Negative Sentiment: Robbins LLP issues a class action notice covering the same class period and urging investor contact. Robbins LLP Notice
• Negative Sentiment: Unusual options activity: traders bought ~23,040 put contracts on Monday (≈27% above typical put volume), signaling increased bearish positioning or hedging demand. Options Activity Report

Boston Scientific Trading Down 2.8%

Shares of NYSE:BSX opened at $69.90 on Wednesday. The firm has a fifty day moving average of $84.03 and a two-hundred day moving average of $93.98. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12-month low of $69.52 and a 12-month high of $109.50. The firm has a market capitalization of $103.72 billion, a P/E ratio of 36.03, a price-to-earnings-growth ratio of 1.01 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period last year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.